RenovoRx Q2 Revenue Jumps 61% Sequentially; FY26 Guidance Raised to $3.75M-$4.25M
RNXT sits 67% above its 52-week low of $0.701.
Summary
RenovoRx reported record Q2 2026 revenue of $909,000, up 61% sequentially and 115% year-over-year, driven by accelerating commercial adoption of its RenovoCath device. The company raised full-year 2026 revenue guidance to $3.75M-$4.25M, up from prior expectations, and now has 21 active commercial cancer center customers, up from 16 at the end of Q1. Management expects Q3 revenue to set another record and reiterated a target of 36 active centers by year-end. The Phase III TIGeR-PaC trial is fully enrolled, with topline data expected in the second half of 2027. This follows the Nasdaq extension granted in July and the first commercial use of RenovoCath in a sarcoma patient reported last week. The company believes a quarterly revenue run-rate of approximately $5 million would achieve cash-flow break-even, which it internally projects for Q4 2027.
At the time of this announcement, RNXT was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.5M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.